AB087. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study

BACKGROUND: Although dapoxetine is the only oral pharmacological agent approved for the treatment of premature ejaculation (PE), and is very effective, the discontinuation rate is high. We assessed the discontinuation rate in patients with PE, and the reasons for discontinuation, in real-world pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Nam Cheol, Kim, Tae Nam, Baek, Seung Ryong, Lee, Kyung Min, Choe, Sangmin, Park, Hyun Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Printed Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186683/
http://dx.doi.org/10.21037/tau.2018.AB087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186683/
http://dx.doi.org/10.21037/tau.2018.AB087

Ejemplares similares